Tufted Angioma Associated With Platelet Trapping Syndrome: Response to Aspirin

Léauté‐Labrèze, Christine; Bioulac‐Sage, Paulette; Labbé, Laurence; Méraud, J.-P.; Taı̈eb, Alain

doi:10.1001/archderm.1997.03890450015001

Cited by 34 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our experience has been uniformly pleasant with the use of these two antiaggregant agents with no bleeding episodes in our patients. Leaute‐Labreze et al published a response to aspirin in a 3‐month‐old infant with TA associated with KMP. Also Frieden and coworker reported the effectiveness of low dose aspirin for large or symptomatic TA that are not associated with KMP.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with kasabach-merritt phenomenon

Fernández-Pineda

López-Gutiérrez

Chocarro

et al. 2013

Pediatr Blood Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with kasabach-merritt phenomenon

Fernández-Pineda

López-Gutiérrez

Chocarro

et al. 2013

Pediatr Blood Cancer

View full text Add to dashboard Cite

show abstract

“…Many cases are reported where aspirin and ticlopidine have been used successfully in combination for the treatment of KMP (Leaute‐Labreze et al , ; Bornet et al , ; Lopez Gutierrez & Patron Romero, ; O'Regan et al , ; Osio et al , ; Barabash‐Neila et al , ). Reports of unsuccessful aspirin and ticlopidine therapy also exist (Enjolras et al , ; Velin et al , ).…”

Section: Coagulopathy‐directed Treatmentmentioning

confidence: 99%

Recent advances in the pathobiology and management of Kasabach–Merritt phenomenon

et al. 2015

View full text Add to dashboard Cite

SummaryKasabach-Merritt Phenomenon (KMP) refers to the clinical constellation of thrombocytopenia, consumptive coagulopathy and purpura associated with Kaposiform haemangioedothelioma or tufted angioma, but not the more common infantile haemangioma. It shows a variable and unpredictable response to traditional pharmacological agents, such as steroids, vincristine or interferon alpha 2a or 2b. More recently, the interaction between platelets and endothelial cells and the proangiogenic phenotype that results has been recognized to underly the pathogenesis of this disorder. Recent efforts have attempted to target the platelet by using antiplatelet agents and by the withholding of platelet transfusions even in those patients who have significant thrombocytopenia and laboratory evidence of coagulopathy. Excellent response rates and prompt results have been achieved by combining antiplatelet therapy with vincristine, without the need for steroid use. This synergistic approach moves away from the conventional wisdom of treating the underlying lesion to control the coagulopathy. Sirolimus, which is directed against the PI3/AKT/ mTOR downstream signalling pathway involved in lymphangiogenesis, has also shown promising results, although further study is needed.

show abstract

“…Larger lesions are at greater risk for underlying KMS. 58 Clinically, a TA manifests as a dusky red to blue, subcutaneous plaque or nodule. Often annular with a wide, palpable border and central depression, the lesion is said to resemble a "doughnut" in the skin.…”

Section: Tufted Angiomamentioning

confidence: 99%